Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and … (NCT06540508) | Clinical Trial Compass
By InvitationNot Applicable
Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
China30 participantsStarted 2023-02-01
Plain-language summary
Application of Integrated Proteomic and Serum Metabolomic Analysis in Efficacy and Prognosis Assessment: A multi-omics analysis based on gut microbiota to evaluate the predictive value of microbial-derived proteins and metabolites on treatment efficacy and patient outcomes, developing non-invasive tools for treatment monitoring and prognostic prediction.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years.
* Histologically or clinically diagnosed with hepatocellular carcinoma (HCC).
* Classified as BCLC stage B/C, not suitable for surgical resection or liver transplantation.
* Planned or already receiving TACE combined with tiragolumab and first-line targeted therapy for liver cancer.
* Not participating in other clinical studies.
* Able to obtain imaging evaluation data and other clinical records during treatment.
Exclusion Criteria:
* Known fibrolamellar HCC, sarcomatoid HCC, or mixed hepatocellular-cholangiocarcinoma histology.
* Tumors involving the main portal vein or inferior vena cava.
* Use of antibiotics within one month before treatment.
* History of other malignancies.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Differences in Macroproteomics and Serum Metabolomics Expression between Effective and Ineffective Treatment Groups.
Timeframe: Starting from the completion of treatment and evaluation for all patients, up to 6 months
2
Model for predicting the efficacy and prognosis of advanced HCC treatment
Timeframe: Within six months after the completion of treatment and evaluation for all patients.
Trial details
NCT IDNCT06540508
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences